With 95% of prescriptions managed by a handful of PBMs, Federal Trade Commission's (FTC) latest interim report exposes the prescription drug middlemen industry and the growing concerns around drug affordability and the survival of independent pharmacies. Here are six key findings from the FTC report on pharmacy benefit managers and its implications for our clients.
To read the full report, visit FTC Releases Interim Staff Report on Prescription Drug Middlemen.
Catalyst Strategies is a full-service government and public affairs firm in Florida. From healthcare policy to tech to local government, we assist our clients with creating and growing momentum for their public policy issues.
Comments